TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced that a subsidiary, Biovail Laboratories International SRL (BLS), has entered into a supply agreement with sanofi aventis US for the marketing and distribution of Aplenzin™ (bupropion hydrobromide tablets) in the United States and Puerto Rico.
